Overview

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Status:
Terminated

Trial end date:
2019-02-25

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 1

Details

Lead Sponsor:

Pediatric Brain Tumor Consortium

Collaborator:

National Cancer Institute (NCI)

Treatments:

Palbociclib